Summary
Treating VY/WfL-Avy/a mice with 5α-androstan-17-one, a mammalian glucose-6-phosphate dehydrogenase inhibitor, prevented the mice from becoming obese. The weight difference between treated and controlAvy/a mice was mainly due to a decreased accumulation of triacylglycerol. The compound did not suppress appetite, had no detectable toxicity and did not affect the lipogenesis rates in the liver and carcass. The weight-controlling effect of 5α-androstan-17-one inAvy/a mice was reversible upon withdrawal of treatment.
Similar content being viewed by others
References
T.T. Yen, J.A. Allan, D.V. Pearson, J.M. Acton and M.M. Greenberg, Lipids12, 409 (1977).
R. Raineri and H.R. Levy, Biochemistry9, 2233 (1970).
T.T. Yen, J.A. Allan, D.V. Pearson, J.M. Acton and M.M. Greenberg, Fedn. Proc.33, 1156 (1977).
T.T. Yen, M.M. Greenberg, P. Yu and D.V. Pearson, Horm. Metabol. Res.8, 159 (1976).
T.T. Yen, J.A. Allan, P. Yu, J.M. Acton and D.V. Pearson, Biochim. biophys. Acta441, 213 (1976).
Author information
Authors and Affiliations
Additional information
The authors wish to thank Mr W.R. Gibson and Drs C.G. Culbertson and P.N. Harris for performing the pathological examinations.
Rights and permissions
About this article
Cite this article
Yen, T.T., Allan, J.A., Pearson, D.V. et al. Control of obesity inAvy/a mice by 5α-androstan-17-one. Experientia 34, 1542–1543 (1978). https://doi.org/10.1007/BF02034660
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02034660